Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

PEP-Therapy Reports Positive Results From GLP-Toxicity Study of PEP-010 Drug Candidate

May 16, 2019 GMT

PARIS--(BUSINESS WIRE)--May 16, 2019--

PEP-Therapy, a biotechnology company developing peptides as targeted therapies for oncology, announces that its first-in-class drug candidate, PEP-010, successfully completed Good Laboratory Practice (GLP) toxicity study, moving towards its first-in-human clinical trial.

PEP-010 was studied in rodent and non-rodent species, in a 4-week toxicity study. The administration schedule was chosen to cover all possible schedules that could be implemented during clinical trial. The study was performed by a world leading CRO specialized in safety and toxicology studies and in accordance with the OECD principles of Good Laboratory Practice as accepted by regulatory authorities.


PEP-010 was well tolerated in rodent and non-rodent species. The study confirmed the absence of systemic toxicity and neuro-behavioural effects, and cardiovascular functions were unaffected by the treatment at all the dose levels. Based on these results, the no-observed-adverse-effect level (NOAEL) was defined and the starting dose for the coming phase I clinical trial calculated.

« The PEP-Therapy team is very pleased with the outcome of this study, which represents a key milestone for the company. The results are very encouraging, PEP-010 is safe and well tolerated at doses significantly higher than those intended to be studied in patients » said Antoine Prestat, CEO and co-founder of PEP-Therapy. « We have now gathered all required preclinical data paving the way for the clinical study ».

Based on these positive results, the Phase I clinical batch and the regulatory documents are in preparation for the submission of a Clinical Trial Application in 2019. PEP-Therapy has entered into a collaborative partnership for Phase I clinical trials with Institut Curie and Gustave Roussy, two leading European cancer centres. The synopsis of the clinical study protocol has been drawn-up for advanced solid tumours. Pr Christophe Le Tourneau (Head of the Department of Drug Development and Innovation (D3i) at Institut Curie) will be the Principal Investigator. « We have been working with PEP-Therapy since the beginning of the project, starting with preclinical work. We are now eager to start the first-in-human clinical trial with a compound that successfully completed GLP-toxicity studies. The Institut Curie is proud to sponsor this clinical trial with such an innovative drug ».

About PEP-Therapy
PEP-Therapy is a medical biotechnology company developing peptides as targeted therapies for oncology.
PEP-Therapy has developed a Cell Penetrating and Interfering Peptide technology (CP&IP) for the development of its therapeutic products. These innovative molecules penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
Founded in January 2014, PEP-Therapy is building on research from Sorbonne University (formerly Pierre and Marie Curie University, UPMC) and Institut Curie. Since its inception, PEP-Therapy has raised 2,5 M€ from Quadrivium 1 seed fund, managed by Seventure Partners, and from Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).
For more details: www.pep-therapy.com


About PEP-010
PEP-010 is PEP-Therapy’s first CP&IP-based product and a first-in-class targeted approach to cancer therapy. PEP-010 specifically blocks the intracellular protein-protein interaction between Caspase-9 and protein phosphatase 2A (PP2A), two major effectors of the apoptosis pathway (programmed cell death).
PEP-010 has completed preclinical proof-of-concept demonstrating significant anti-tumour activity in patient-derived xenograft (PDX) models. Repeated GLP-toxicity studies showed a good tolerance of the product. Phase I clinical regulatory documents are in preparation for submission of a Clinical Trial Application shortly.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005436/en/

Antoine Prestat, CEO – +33 1 53 10 05 48 –hello.pep@pep-therapy.com




Copyright Business Wire 2019.

PUB: 05/16/2019 08:30 AM/DISC: 05/16/2019 08:30 AM